TrialBritish journal of clinical pharmacology2017

First-in-human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL-17A and IL-17F, in mild psoriasis.

Sophie Glatt et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.